Compare

Unicycive Therapeutics/$UNCY

1D1W1M3M6MYTD1Y5YMAX

About Unicycive Therapeutics

Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Ticker
$UNCY
Sector
Health
Primary listing
NASDAQ
Employees
22

UNCY Metrics

BasicAdvanced
$99M
-
-$1.56
1.78
-

What the Analysts think about UNCY

Analyst ratings (Buy, Hold, Sell) for Unicycive Therapeutics stock.
Analyst projections of the future price of Unicycive Therapeutics stock.

UNCY Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

UNCY Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing UNCY

Funds
Fund name
Fund size
$UNCY weighting
SPDR Russell 2000 US Small Cap€R2US
$5.3B0.00%
SPDR Russell 2000 US Small Cap£R2SC
$5.3B0.00%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.